VERAXA Biotech AG (NASDAQ: VRXA) has released new in vitro proof-of-concept data supporting its BiTAC-ADC platform, a technology designed to improve the selectivity of antibody-drug conjugates (ADCs) in cancer treatment. The company, which recently began trading on the NASDAQ Capital Market following a business combination with Voyager Acquisition Corp., presented the findings as it prepares to engage with potential pharmaceutical and biotechnology partners at the BIO International Convention 2026 in San Diego (https://nnw.fm/APy2D).
The data demonstrated that VERAXA's BiTAC-ADC technology could distinguish between breast cancer cells and healthy cells in laboratory studies, showing dose-dependent destruction of three-dimensional tumor cell spheroids. While the platform remains in early development, these results suggest a potential advancement in precision oncology, aiming to reduce off-target toxicities commonly associated with traditional ADCs.
VERAXA's proprietary BiTAC (Bispecific T-cell Adaptor and Converter) approach is designed to activate therapeutic effects only in targeted tumor cells. The company maintains a diversified oncology pipeline of antibody-based formats, including ADCs, T-cell engagers (TCEs), and other antibody-based formats. The BiTAC platform can be applied to both ADCs and TCEs, potentially enhancing their specificity and efficacy.
The announcement comes as VERAXA seeks to establish strategic collaborations to advance its pipeline. The company will present its BiTAC-ADC and BiTAC-TCE platforms at the BIO International Convention, a major industry event where biotechnology companies showcase technologies to attract partners. VERAXA's leadership believes that its technology could address key limitations of current cancer therapies, particularly the challenge of targeting tumor cells without harming healthy tissue.
In addition to the BiTAC platforms, VERAXA's pipeline includes other antibody-based candidates. The company's recent listing on NASDAQ provides access to capital markets to support its research and development efforts. Investors can find the latest news and updates about VERAXA on the company's newsroom (https://nnw.fm/VRXA).
The in vitro data, while encouraging, require further validation in animal models and clinical trials. The company has not disclosed timelines for advancing the BiTAC-ADC program into clinical development. However, the initial results mark a step forward for VERAXA's mission to design next-generation cancer therapies with improved precision and reduced side effects.
